Day TwoWednesday, 30 April 2025 - GMT (Greenwich Mean Time, GMTZ)

Biotech and pharma spin-outs are increasingly emerging as powerful players in the development of novel therapies, often leveraging cutting-edge technologies and scientific advancements. These spin-outs are frequently born from larger institutions or partnerships with established pharmaceutical companies, aiming to bring fresh ideas and new solutions to complex medical challenges. With the right mix of capital, strategic partnerships, and visionary leadership, these companies can accelerate the development of groundbreaking treatments. This panel will explore the current landscape of biotech/pharma spin-outs, examining the factors that drive successful investments, the role of venture capital in de-risking innovation, and how investors can foster long-term growth in this high-stakes sector.

• The role of VC in accelerating spin-outs and identifying high-potential biotech assets
• Exploring how spin-outs benefit from collaborations with larger pharmaceutical companies, licensing agreements, and how these partnerships can provide both funding and expertise
• Understanding the risks associated with investing in biotech/pharma spin-outs, especially in emerging fields like T cell engagers and immunology, and how investors manage these risks for long-term rewards
• The challenges and opportunities in funding spin-outs with clinical-stage assets, including the transition from discovery-stage research to IND-enabling studies, and how investors play a role in ensuring clinical progress and trial success